Use of proteasome inhibition in the treatment of lung cancer

Clinical Lung Cancer

Volumn 6, Issue SUPPL. 2, 2004, Pages

  Schenkein, David P ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Bcl 2; Bortezomib; Combination therapy; Gemcitabine; Non small cell lung cancer; Nuclear factor B; Small cell lung cancer; Taxanes

Indexed keywords

ADENOSINE DIPHOSPHATE; BIOLOGICAL MARKER; BORTEZOMIB; CARBOPLATIN; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; DOCETAXEL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FLUOROURACIL; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; PACLITAXEL; PLATINUM DERIVATIVE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MDM2; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; TAXANE DERIVATIVE; UBIQUITIN; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ADVANCED CANCER; ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CLINICAL TRIAL; DRUG APPROVAL; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; DRUG USE; GENE TARGETING; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE MYELOMA; PHARMACOGENOMICS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIDE EFFECT; TUMOR GROWTH;

EID: 12744260116     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2004.s.021     Document Type: Article

References (59)

1. Grigorescu AC, Draghici IN, Nitipir C, et al. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer 2002; 37:9-14.
2. Mazzanti P, Massacesi C, Rocchi MB, et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2003; 41:81-89.
3. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20:4285-4291.
4. Zatloukal P, Petruzelka L, Zemanova M, et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer a phase III randomized trial. Lung Cancer 2003; 41:321-331.
5. Ramalingam S, Belani CP. Carboplatin/gemcitabine combination in advanced NSCLC. Oncology (Huntingt) 2004; 18:21-26.
6. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102:1115-1123.
7. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127:165-172.
8. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
9. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999; 68:1015-1068.
10. DeMartino GN, Slaughter CA. The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem 1999; 274:22123-22126.
11. Benaroudj N, Zwickl P, Seemuller E, et al. ATP hydrolysis by the proteasome regulatory complex PAN serves multiple functions in protein degradation. Mol Cell 2003; 11:69-78.
12. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998; 17:7151-7160.
13. Kisselev AF, Garcia-Calvo M, Overkleeft HS, et al. The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J Biol Chem 2003; 278:35869-35877.
14. Kisselev AF, Akopian TN, Castillo V, et al. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol Cell 1999; 4:395-402.
15. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4:349-360.
16. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003; 426:895-899.
17. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001; 8:739-758.
18. Benaroudj N, Tarcsa E, Cascio P, et al The unfolding of substrates and ubiquitin-independent protein degradation by proteasomes. Biochimie 2001; 83:311-318.
19. Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998; 8:333-338.
20. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59:2615-2622.
21. Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003; 9:1145-1154.
22. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7:1419-1428.
23. Denlinger CE, Rundall BK, Keller MD, et al. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 2004; 78:1207-1214.
24. Gumerlock PH, Kawaguchi T, Moisan LP, et al. Mechanisms of enhanced cytotoxicity from docetaxel-PS-341 combination in non-small cell lung carcinoma. Proc Am Soc Clin Oncol 2002; 21:304a (Abstract #1214).
25. Mortenson MM, Schlieman MG, Virudachalam S, et al. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 2004; 54:343-353.
26. Yang Y, Ikezoe T, Saito T, et al. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-jun/AP-1 signaling. Cancer Sci 2004; 95:176-180.
27. Ling YH, Liebes L, Ng B, et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 2002; 1:841-849.
28. Yu J, Tiwari S, Steiner P, et al. Differential apoptotic response to the proteasome inhibitor bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells. Cancer Biol Ther 2003; 2:694-699.
29. Zetter BR. Adhesion molecules in tumor metastasis. Semin Cancer Biol 1993; 4:219-229.
30. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277:16639-16647.
31. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001; 100:11-17.
32. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997; 57:3381-3385.
33. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000; 60:3689-3695.
34. Ling YH, Liebes L, Zou Y, et al. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003; 278:33714-33723.
35. Mack PC, Davies AM, Lara PN, et al. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer 2003; 41(suppl 1):S89-S96.
36. Teicher BA, Ara G, Herbst R, et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5:2638-2645.
37. Yunmbam MK, Li QQ, Mimnaugh EG, et al. Effect of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells. Int J Oncol 2001; 19:741-748.
38. Fanucchi MP, Belt RJ, Fossella FV, et al. Phase (ph) 2 study of bortezomib ± docetaxel inpreviously treated patients (pts) with advanced non-small cell lung cancer (NSCLC). Preliminary results. J Clin Oncol 2004; 22(suppl 14S):643s.
39. Stevenson J, Nho CW, Johnson SW, et al. Phase II /pharmacodynamic trial of PS-341 (bortezomib, VELCADE®) in advanced non-small cell lung cancer. J Clin Oncol 2004; 22(suppl 14S):652s.
40. National Institutes of Health. Gemcitabine, carboplatin, and bortezomib in treating patients with advanced of recurrent non-small cell lung cancer. Located at: clinical-trials.gov/ct/gui/show/NCT00075751?order=2. Accessed October 21, 2004.
41. National Institute of Health. Bortezomib, paclitaxel, and carboplatin combined with radiation therapy in treating patients with stage IIIA or stage IIIB non-small cell lung cancer that cannot be removed by surgery. Located at: clinicaltrials.gov/ ct/gui/show/NCT00093756?order=1. Accessed October 21, 2004.
42. Aghajanian C, Soigner S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8:2505-2511.
43. Davies AM, Lara PN, Lau D, et al. MTD determined for the proteasome inhibitor, bortezomib, in combination with gemcitabine (gem) and carboplatin (carbo) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004; 22(suppl):642s (Abstract #7106).
44. Appleman LJ, Ryan DP, Clark JW, et al. Phase I dose escalation study of bortezomib and gemcitabine safety and tolerability in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2003; 22:209 (Abstract #839).
45. Shepherd FA. Current paradigms in first-line treatment of non-small-cell lung cancer. Oncology (Huntingt) 2004; 18:13-20.
46. Gandara DR, Vokes E, Green M, et al. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 2000; 18:131-135.
47. Albanell J, Baselga J, Guix M, et al. Phase I study of bortezomib in combination with docetaxel in anthracycline-pretreated advanced breast cancer. Proc Am Soc Clin Oncol 2003; 22:16 (Abstract #63).
48. Dreicer R, Roth B, Petrylak D, et al. Phase I/II trial of VELCADE® plus docetaxel in patients with advanced androgen-independent prostate cancer. J Clin Oncol 2004; 22(suppl 14s):420s.
49. Lara PN, Quinn DI, Koczywas M, et al. The proteasome inhibitor bortezomib plus docetaxel (DOC) in advanced non-small cell lung cancer (NSCLC) and other solid tumors: a phase I California Cancer Consortium trial. Presented at the 10th World Congress of the International Association for the Study of Lung Cancer; August 10-14, 2003; Vancouver, BC, Canada.
50. Messersmith WA, Baker SD, Dinh K, et al. Phase I trial of bortezomib (PS-341) in combination with docetaxel in patients with advanced solid tumors. J Clin Oncol 2004; 22(suppl 14s):3052.
51. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
52. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500.
53. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323:561-565.
54. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8:816-824.
55. Stefanaki K, Rontogiannis D, Vamvouka C, et al. Immunohistochemical detection of bcl2, p53, mdn2 and p21/waf1 proteins in small-cell lung carcinomas. Anticancer Res 1998; 18:1689-1695.
56. Fennell DA. Bcl-2 as a target for overcoming chemoresistance in small-cell lung cancer. Clin Lung Cancer 2003; 4:307-313.
57. Pervan M, Pajonk F, Sun JR, et al. Molecular pathways that modify tumor radiation response. Am J Clin Oncol 2001; 24:481-485.
58. Russo SM, Tepper JE, Baldwin AS Jr, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001; 50:183-193.
59. Lebowitz PF, Harkins C, Conley B, et al. Concomitant therapy with proteasome inhibitor, bortezomib, and radiation in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Proc Am Soc Clin Oncol 2003; 22:499 (Abstract #2010).